Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that members of its management team will participate in two investor conferences in August and September 2026. President and Chief Executive Officer Dr. Seth Lederman will take part in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Aug. 11 from 1:30 p.m. to 1:55 p.m. ET. The company also said Lederman will participate in one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Sept. 16. The events provide Tonix an opportunity to discuss its business and engage with the investment community.
This announcement is significant as it highlights Tonix's ongoing efforts to communicate its strategic vision and pipeline progress to investors. The company is a fully-integrated, commercial-stage biotechnology firm focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years, marking a major milestone in CNS therapeutics. The recent approval of TONMYA positions Tonix to address a substantial patient population, and the company is now exploring its potential in other indications.
Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. The company is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. These initiatives reflect Tonix's commitment to expanding its CNS franchise beyond fibromyalgia.
Beyond CNS, Tonix is advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs highlight the company's diversification into immunology, addressing significant unmet needs in infectious diseases and transplant medicine. The upcoming conference presentations will likely provide updates on these programs and the overall corporate strategy.
Investors and industry observers will be keen to hear Dr. Lederman's insights during the fireside chat and one-on-one meetings. The conferences offer a platform for Tonix to articulate its growth plans, discuss recent achievements, and outline upcoming milestones. This engagement is crucial for maintaining investor confidence and attracting potential partners.
For more information, visit the company's newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/DKFAC.
